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OBJECTIVES: Few reports of dialysis patient satisfaction
with care have been published. Dialysis Clinic, Inc. (DCI),
a nation-wide, not-for-proﬁt dialysis provider, devised 
a patient satisfaction questionnaire (PSQ) for routine
administration. It contains 9 items with a Likert response
scale of excellent to poor assessing patient perspectives
on: staff, treatment, professionalism, teamwork, respect,
timeliness, involvement, the clinic, and overall satisfac-
tion. Based upon available literature, we hypothesized
that older patients, women, whites, and peritoneal 
dialysis (PD) patients would be more satisﬁed.
METHODS: We examined PSQ results obtained by self-
administration between April 1999 and March 2000. The
item for overall satisfaction was used in these analyses.
Because of uneven distribution, responses were analyzed
as a dichotomized variable of excellent and very good
(EVG) or good, fair and poor (GFP). Patients excluded
were either not present at administration, cognitively
impaired, or non-English speaking. Differences in contin-
uous variables were analyzed by Wilcoxon Rank Sum test
and those for categorical variables utilized Chi-square
testing.
RESULTS: N = 7,037, 40.4% ≥ 65 years, 53.2% male,
48.8% white, and 13.4% on PD. 76.4% had a score of
EVG. Patients ≥ 65 years were more satisﬁed (79.5%
scoring EVG) than patients < 65 (74.2% scoring EVG) 
(p =< 0.0001). There was no signiﬁcant difference
between men and women. White patients (84.7% scoring
EVG) were more satisﬁed than non-white patients
(68.4% scoring EVG) (p =< 0.0001). PD patients (93.6%
scoring EVG) were more satisﬁed than hemodialysis
patients (73.7% scoring EVG) (p =< 0.0001).
CONCLUSION: The sample population is representative
of the overall United States dialysis population except 
for a lower percentage of white patients reported. This
study indicates older patients, whites, and PD patients
were more satisﬁed than other dialysis patients. Any
group comparisons of satisfaction in this population
should adjust for demographic factors. This will assist
with the incorporation of patient involvement into health-
care delivery.
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OBJECTIVES: Treatment of overactive bladder (OAB)
with tolterodine impacts positively on many aspects of
health related quality of life as measured by the King’s
Health Questionnaire (KHQ). Physical (Incontinence
Impact, Role Limitations, and Physical Limitations) and
symptom (Severity Measures and Symptom Severity)
domains were signiﬁcantly improved after 12 weeks of
treatment. In this study, we report the results of an addi-
tional 12 months of open-label therapy.
METHODS: This two-part multinational study evaluated
the efﬁcacy and safety of tolterodine. In Phase A, a 12-
week double-blind study, OAB patients with incontinence
(n = 1529) were randomized to receive tolterodine (4mg
LA or 2mg IR) or placebo. Of these, 874 received active
treatment and completed at least one KHQ. In Phase B,
838 patients continued on for an additional 12 months
open-label tolterodine LA, completing the KHQ at 3 and
12 months. LSMeans between time-points in Phase B
were calculated using a split-plot ANCOVA with repeated
measures; visits and treatment group as factors and age,
gender and country as covariates. P-values were corrected
for multiple comparisons using the Hochberg procedure
with the initial level of alpha set at 0.05.
RESULTS: Signiﬁcant positive effects on physical and
symptom related domains persisted for an additional 12
months of therapy. Further improvements were seen after
3 and 12 months of open-label treatment in Incontinence
Impact and Role Limitations domains. Other physical
and symptom domains were further improved at 3
months. Treatment effects on other domains have been
reported previously.
CONCLUSIONS: Physical and symptom domains scores
of the KHQ improved with tolterodine treatment and
these improvements persisted with continued treatment.
Incontinence Impact and Role Limitations both showed
improvements beyond the initial treatment gains achieved
during the ﬁrst 12 weeks of blinded treatment. These
results support the long-term use of tolterodine in 
the treatment of OAB patients experiencing urinary
incontinence.
PUK12
HOW RESPONSIVE IS THE OVERACTIVE
BLADDER QUESTIONNAIRE (OAB-Q) TO
CHANGES IN URGENCY, FREQUENCY,AND
INCONTINENCE?
Tomera KM1, Coyne K2, Matza LS2, Corey R3
1Alaska Clinical Research Center, Anchorage, AK, USA;
2MEDTAP International, Inc, Bethesda, MD, USA; 3University of
the Sciences in Philadelphia, Pharmacia Corporation, Peapack,
NJ, USA
OBJECTIVE: The psychometric properties of the 25-item
OAB-q have been previously documented in overactive
bladder (OAB) patients, however responsiveness has not.
This study was to assess OAB-q’s responsiveness to
changes in urgency episodes as well as frequency and
incontinence during antimuscarinic therapy of OAB
patients.
279Abstracts
METHODS: OAB patients were treated with Tolterodine
Extended Release LA 4mg/day for 12 weeks. Patient 
evaluation included the OAB-q, urgency and incontin-
ence episodes, micturition frequency, and perception of
bladder condition at baseline, 4 and 12 weeks. Patient
and physician assessments of treatment beneﬁt were
obtained at 4 and 12 weeks. The OAB-q includes a
symptom bother scale, 4 HRQL subscales (coping,
concern, sleep, social interaction) and a total HRQL
score. Responsiveness was examined with effect sizes and
comparisons to other measures of treatment efﬁcacy using
ANOVAs, t-tests, and correlations.
RESULTS: A total of 865 patients completed the 12 
week study; mean age was 61 years with 73% female and
89% Caucasian. Signiﬁcant improvements occurred in 
all OAB-q subscales from baseline to 4 weeks and were
maintained through week 12 with additional improve-
ments noted. A reduction of 3 or more micturitions per
day resulted in signiﬁcant OAB-q score changes (10 to 
28 points, p < 0.05). Reducing the number of urgency
episodes per day by 3 resulted in signiﬁcant changes in all
OAB-q subscale scores (p < 0.05). As expected, reduction
of 1 or more incontinence episodes per day also corre-
sponded to OAB-q score changes (p < 0.05).
CONCLUSION: This is the ﬁrst report demonstrating
responsiveness of the OAB-q in relation to reduction in
urgency, as well as frequency and incontinence episodes,
following antimuscarinic therapy.
